Psych
Female Sexual Dysfunction
search
Female Sexual Dysfunction
, Sexual Dysfunction, Female Sexual Arousal Disorder
See Also
Dyspareunia
Vaginismus
Chronic Pelvic Pain
Antidepressant Induced Sexual Dysfunction
Sexual Dysfunction from Medications
Erectile Dysfunction
Epidemiology
Women with sexual concerns: >50%
American women who have never had an orgasm: 8%
Types
Disorders of Sexual Desire and Arousal
Female sexual interest/arousal Disorder (DSM5)
Symptoms for >=6 months and associated with significant distress in the individual
Lack or significant decrease in at least 3 of the following
Interest in sexual activity
Sexual or erotic thoughts or fantasies
Initiation of sexual activity and responsiveness to a partner's initiation
Excitement or pleasure during all or almost all sexual activity
Interest or arousal in response to internal or external sexual cues
Genital or nongenital
Sensation
s during sexual activity in nearly all sexual encounters
Hypoactive Sexual Desire Disorder (ICSM/ISSWSH)
Symptoms for >=6 months
Any of the following
Lack of motivation for sexual activity (low sex drive, libido)
Reduced or absent spontaneous desire
Reduced or absent responsive desire to erotic cues and stimulation
Reduced or absent ability to maintain desire or interest through sexual activity
Loss of desire to initiate or participate in sexual activity
Avoidance of situations that could lead to sexual activity
Not secondary to sexual
Pain Disorder
Female Cognitive Arousal Disorder (ICSM/ISSWSH)
Symptoms for >=6 months, with problems feeling engaged or sexually aroused
Distressing difficulty to maintain mental excitement associated with sexual activity
Female Genital Arousal Disorder (ICSM/ISSWSH)
Symptoms for >=6 months
Distressing difficulty to maintain adequate genital response (e.g. lubrication, engorgement, sensitivity)
Includes neurovascular injuries or dysfunction
May result in
Dyspareunia
(due to lack of lubrication)
Persistent Genital Arousal Disorder (ICSM/ISSWSH)
Symptoms for >=6 months
Recurrent genital dysesthesia/distress related to arousal or verge of orgasm
Arousal that is unwanted, intrusive, distressing
Not associated with sexual interest, thoughts or fantasies
Other associations
Aggravation of genital symptoms by sexual activity or other circumstances
Significant secondary emotional distress
Active revulsion from sexual stimulation
Types
Female Orgasmic Disorder (DSM5, ICSM/ISSWSH)
Symptoms for >=6 months, affecting nearly all sexual activity, and associated with significant distress
Persistent or recurrent compromise of orgasm frequency, intensity, timing or pleasure
Orgasm absent (anorgasmy), significantly delayed or infrequent OR
Significantly reduced intensity of orgasmic
Sensation
s
Types
Genito-
Pelvic Pain
and Penetration Disorders (DSM5 and ICSM/ISSWSH)
See
Dyspareunia
See
Vaginismus
Symptoms >=6 months and with significant distress to the individual
Persistent or recurrent problems with 1 or more of the following
Difficulty with vaginal penetration during intercourse
Marked vulvovaginal or
Pelvic Pain
during intercourse or penetration attempts
Marked fear or anxiety about vulvovaginal or
Pelvic Pain
before, during or after vaginal penetration
Marked tensing or tightening of the pelvic floor
Muscle
s during attempted vaginal penetration
Causes
Psychological and Social
Mood Disorder
Major Depression
Guilt about past sexual activities
Masturbation
Premarital and extramarital sex
Sexually Transmitted Infection
Abortion
Multiple partners
Sexual abuse history
Substance Abuse
Relationship problems
Marital distress
Couple mismatch on sexual preferences
Frequency of intimacy
Variety of intimate activities
Causes
Drugs Affecting Sexual Desire Phase
See
Antidepressant Induced Sexual Dysfunction
(
SSRI
,
SNRI
,
Tricyclic Antidepressant
s)
See
Sexual Dysfunction from Medications
CNS Depressant
s
Alcohol
Sedative-Hypnotic
s (
Benzodiazepine
s,
Barbiturate
s)
Monoamine Oxidase Inhibitor
s (
MAO Inhibitor
s)
Antianxiety agents
Opioid
s
Antipsychotic
s (e.g.
Haloperidol
,
Risperidone
)
Lithium
Antiepileptic agents
Carbamazepine
Phenytoin
Topiramate
Valproic Acid
Cardiovascular Medications
Beta Blocker
s
Clonidine
Methyldopa
Digoxin
Spironolactone
Thiazide Diuretic
s
Statin
s
Hormonal Agents
Antiandrogens
Aromatase Inhibitor
s
GnRH Agonist
s and analogues
Hormonal contraceptives
Selective Estrogen Receptor Modulator
(e.g.
Tamoxifen
)
Miscellaneous agents
Cancer
Chemotherapy
agents (e.g. ovary damage)
Cimetidine
or
Ranitidine
(antiandrogen)
Anticholinergic Medication
s (including
Antihistamine
s)
Chemical abuse (may variably enhance libido)
Cocaine
Amphetamine
s
Hallucinogen
s
Marijuana
Causes
Medical Conditions
Genital anatomy changes
Gynecologic cancer
Hysterectomy
Radiation Therapy
Nerve dysfunction
Diabetes Mellitus
Multiple Sclerosis
Neuromuscular disorders
Parkinsonism
Traumatic Brain Injury
Trauma
tic
Paraplegia
Pituitary tumor (or
Hyperprolactinemia
)
Decreased
Estrogen
Oophorectomy
Premature Ovarian Failure
Menopause
Other gynecologic disorders
Polycystic Ovary Syndrome
Pelvic Floor Disorder
s
Endometriosis
Disruption of body image
Ostomy
Mastectomy
Urinary Incontinence
Miscellaneous conditions
Coronary Artery Disease
Hypothyroidism
End-stage Renal Disease on
Dialysis
History
Sexually Active?
Any sexual concerns?
Do you have any concerns about sexual desire, sexual arousal or orgasm?
Do you have any genital symptoms?
Vaginal Dryness
or lack of lubrication?
Vaginal pain or burning (
Vaginismus
)
Painful Intercourse
(
Dyspareunia
)?
Management
Gene
ral
Entitlement to sexual satisfaction
Permission to initiate sex
Permission to ask for more stimulation from partner
Permission to ask for specific types of stimulation
Permission to refuse sex when not interested
Distribution of Information
Educate (e.g. Women require longer excitement phase)
Dispel myths (e.g. masturbation is abnormal)
Demonstrate on diagrams sexual anatomy and physiology
Specific Suggestions
Privacy from children
Modify sexual behavior for physical
Impairment
s
Consider changing sexual time of day or location
Allow more time for sexual arousal and excitement
Emphasize physical intimacy over the goal of orgasm
Consider changes to medications
See
Antidepressant Induced Sexual Dysfunction
See
Sexual Dysfunction from Medications
Treat underlying conditions
See
Dyspareunia
See
Vaginismus
See
Chronic Pelvic Pain
See
Menopause
recommendations below (e.g.
Vaginal Dryness
)
Consider referral
Sex Therapist (AASECT)
http://www.aasect.org/
Marriage and Family Therapist
https://www.aamft.org/iMIS15/AAMFT/
Chronic Pelvic Pain
Specialist
http://www.pelvicpain.org/
Management
Female Sexual Interest/Arousal Disorder
First-Line
Cognitive Behavioral Therapy
Mindfulness
Couples therapy
Second Line: Medications for low sexual desire in premenopausal women
Agents are minimally effective and expensive ($400 to $900 per month in 2019)
Flibanserin
(
Addyi
) oral tablet daily
Bremelanotide (Vyleesi) injected SQ (
Abdomen
or thigh) prn 45 minutes before sexual activity
Limit to one dose in 24 hours and 8 in one month
Avoid use in
Uncontrolled Hypertension
or cardiovascular disease
Adverse effects include
Nausea
and
Vomiting
(1 in 8 need an
Antiemetic
)
May result in
Hyperpigmentation
of possibly irreversible face,
Breast
s, gums
(2019) Presc Lett 26(8): 54
Third Line (off-label, not FDA approved)
Bupropion
Topical
Testosterone
(postmenopausal women)
Management
Other Specific Management
Female Orgasmic Disorders
Cognitive Behaviousl Therapy
Sex Therapy (including directed masturbation)
Vibrators
Genito-Pelvic
Pain Disorder
s
See
Chronic Pelvic Pain in Women
See
Vaginismus
See
Dyspareunia
)
Comprehensive evaluation
Pelvic Floor Physical Therapy
Pelvic Floor Dysfunction
Pelvic Floor Physical Therapy
Vaginal Dilators (second-line)
Management
Postmenopausal
Gene
ral
Sexual interest related to partner's interest in sex
Estrogen
Loss may decrease sexual interest
Hot Flashes
Dyspareunia
Vaginal Dryness
Vaginal lubrication requires more stimulation
Weaker orgasmic contractions
First-Line Medications
See
Vaginal Dryness
Vaginal Estrogen
cream
Water soluble
Vaginal Lubricant
s (e.g. Astroglide)
Second-Line Medications
Vaginal
DHEA
Ospemifene
References
McCartney in Dornbrand (1992) Ambulatory Care, p. 380-3
Clayton (2003) Psychiatr Clin North Am 26:673-82 [PubMed]
Dalrymple (2025) Am Fam Physician 111(5): 433-42 [PubMed]
Faubion (2015) Am Fam Physician 92(4): 281-8 [PubMed]
Philips (2000) Am Fam Physician 62(1):127-36 [PubMed]
Type your search phrase here